Once studied, the cardiovascular effects of tirzepatide will likely be similar to GLP-1 RAs
Always consult with your healthcare provider for personalized advice and guidance
Some GLP-1 RAs (albiglutide, efpeglenatide, dulaglutide, liraglutide, and once-weekly semaglutide) reduce the risk of major adverse cardiovascular events (MACE) in people with type 2 diabetes (T2D) with established CVD or at high risk of CVD [19,20,21,22,23]
Patients who combine these medications with intentional nutrition, strength training, and medical guidance are more likely to maintain muscle mass, protect bone density, and sustain metabolic health while losing weight.
This question is crucial, as adhering to storage recommendations ensures that the medication remains potent and effective for its intended purpose
Development of a first-in-class unimolecular dual GIP/GLP-2 analogue, GL-0001, for the treatment of bone fragility